nl-scn2a-002
Nucleic acidexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 16, 2024 (NCT06314490)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sodium channel protein type II alpha subunitANTISENSE INHIBITOR
SCN2A antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06314490 | Phase 1/Phase 2 (Phase 2) | Feb 16, 2024 | California Institute for Regenerative Medicine (CIRM), n-Lorem Foundation, University of California, San Diego |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| n-Lorem Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1